KAT6A and acute myeloid leukemia: Moreover, inhibition of MOZ histone acetyltransferase (KAT6A) with compounds such as PF9363 has shown efficacy in reducing the viability of AML cells with NUP98 rearrangement and prolonging survival in mouse models, highlighting the role of epigenetic regulators as therapeutic targets.